Selpercatinib capsules 40 mg/capsule, 120 capsules/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Hepatotoxicity: ALT and AST should be monitored prior to starting LUCISEL, every 2 weeks for the first 3 months, and monthly thereafter, as clinically indicated. Suspend, reduce the dose, or permanently discontinue Lucisel, depending on the severity.
• Interstitial lung disease (ILD)/pneumonia: Monitor for new or worsening lung symptoms. Suspend, reduce the dose, or permanently discontinue Lucisel, depending on the severity.
• Blood Pressure: Do not use Lucisel in patients with uncontrolled blood pressure. Optimize blood pressure (BP) before starting LUCISEL. Monitor blood pressure after 1 week, and at least monthly thereafter, as clinically indicated. Suspend, reduce the dose or permanently discontinue Lucisel, depending on the severity.
• QT prolongation: Surveillance of patients at significant risk of QTc prolongation. The QT interval, electrolytes, and TSH at baseline were assessed periodically during and during treatment. The QT interval should be monitored more frequently when Lucisel is used in conjunction with potent and intermediate CYP3A inhibitors or medications known to prolong the QTc interval. Suspend and reduce the dose or permanently discontinue LUCISEL according to the severity.
• Bleeding events: For patients with severe or life-threatening bleeding, permanently discontinue LUCISEL.
• Allergies: Suspend Lucisel and start corticosteroids. After symptom relief, recover at a lower dose and increase the dose by 1 dose level per week until the dose taken before the onset of allergy is reached. Continue using the steroid until the patient reaches the target dose and then gradually decrease.
• Tumor lysis syndrome: at-risk patients are closely monitored and treated as clinically indicated.
• Risk of impaired wound healing: discontinue LUCISEL at least 7 days prior to elective surgery. Do not administer for at least 2 weeks after major surgery until the wound has fully healed. The safety of LUCISEL recovery after resolution of wound healing complications has not been determined.
• Hypothyroidism: Thyroid function is regularly monitored before and during treatment with LUCISEL. Interrupt treatment according to severity until clinically stable or permanently discontinued.
• Embryo-fetal toxicity: May cause harm to the fetus. Women of childbearing potential are advised to be aware of possible risks to the fetus and to use effective contraception.
• Pediatric patient with epiphysis/suprafemoral epiphysis (SCFE/SUFE): Monitor the patient for symptoms of SCFE/SUFE and treat appropriately according to medical and surgical conditions.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 25%) include:
• Adult patients with solid tumors: edema, diarrhea, fatigue, dry mouth, Blood Pressure, abdominal pain, constipation, rash, nausea, and headache.
• Children with solid tumors: musculoskeletal pain, diarrhea, headache, nausea, vomiting, coronavirus infection, abdominal pain, fatigue, fever, and bleeding.
The most common Grade 3 or 4 laboratory abnormalities (≥ 5%) include:
• Adult patients with solid tumors: decreased lymphocytes, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), decreased sodium, and decreased calcium.
• Children with solid tumors: calcium decreased, hemoglobin decreased and neutropenia.